Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
about
SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactionsGelatinase B/MMP-9 in Tumour Pathogenesis and ProgressionExtracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomesThe behavior of matrix metalloproteinases and their inhibitors in colorectal cancerStructural basis of Ets1 cooperative binding to palindromic sequences on stromelysin-1 promoter DNAPutting tumours in contextAlternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinaseIL-1 is required for tumor invasiveness and angiogenesisAnti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivoCompensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysisImaging and quantifying the dynamics of tumor-associated proteolysis.Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?Requirement for Arf6 in breast cancer invasive activities.Pancreatic cancer: pathobiology, treatment options, and drug delivery.ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors.Matrix metalloproteinases, T cell homing and beta-cell mass in type 1 diabetes.Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation.Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.Metalloproteinase binding proteins: WO2009097397.Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancerRole of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptidesTumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma.Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo.Functional screen of paracrine signals in breast carcinoma fibroblasts.Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls.Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis.Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeuticsTetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9.Mechanisms of tumour invasion and metastasis: emerging targets for therapy.Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer.A diastereoselective formal synthesis of berkelic acid.Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9Advances in molecular therapies in patients with brain tumors.
P2860
Q24550889-CA811F6F-9BB1-4D25-ACC8-257C886B9AEEQ24568374-F14840DF-C85D-4079-9C58-E04A9F839045Q26825792-24AD6340-C356-4F80-A96E-D39505BE646FQ27004958-B9815A4E-D6C5-4B14-8419-301CE579B008Q27663883-FE5EAA33-9D1E-4324-BBCD-A43EC5FD2F45Q28207789-531B0FDB-5BB2-462D-A3D6-A5C88102B3CCQ28217222-57DCE5BE-6B12-4E35-9595-9FF2CFADEC5EQ28594748-BAC3C2EA-E136-4059-87DA-C779E45B84B8Q28727262-D42C0CA0-DE7C-4B1C-82E9-18BF86F778A4Q29615193-162FB6B9-4CE3-4C5E-8D80-3D64C2ED93A2Q30497465-CC7A8CB4-AF69-4531-A58B-AD261F56B4A7Q30540289-7105A020-83E5-40E0-B7AB-ADADDBDE5528Q33619919-6CBA0253-40A4-41B3-94DF-1849506A34ADQ33691403-77578F86-FE62-4BE4-B756-A43BB58D5FEBQ33696335-95C9D788-7809-4569-A14D-36E7B50AE80DQ33749460-71D025BC-3663-4DE0-94CF-3160B81DCF4EQ33794994-63E2B9F4-5B70-4D30-AEF9-CA59867FBF48Q33797703-6E87F25A-59DD-420B-9DFC-BBC3CABCBECCQ33880433-5612C195-8B6A-458A-9D37-87A1CF45852FQ33905175-15A5E537-189C-4B82-973C-AA66D82BDB4AQ34030049-9AB6633C-3ABD-4EE6-91D0-FC246A7C1F93Q34049288-37F626B3-8CCB-4EBE-BFE6-1CF3A34613DEQ34055529-E367302E-A257-47A8-A817-8EE378B28D6FQ34285372-B209BF55-CCE8-4404-9812-FB999089CF86Q34364766-F70F565E-BB13-49B7-B07F-0654B173299CQ34411893-23E6CBFB-EDFF-4EA9-8F14-6B6BA7301FB9Q34441858-E3194E81-A7DF-471D-BDE4-C04D25D402B1Q34463741-5C6A8CC3-8159-4CD7-9CDD-3257DDFD95BEQ34542007-A5D56BFE-EC98-410A-BA60-EAEB2F377E18Q34616803-21E3470E-B859-4213-93AB-8F346F464BD5Q34706690-1B64F1FF-C885-4DF1-BC2F-AFB63695ACE1Q34731111-24A6FE84-4E95-4826-8790-D81094076E87Q34808021-128C3ABA-F55C-419E-A20D-41E1AA33F298Q34837655-B9F5391E-44AB-4D91-98D2-387C5A5614CEQ34985930-F799A004-01C3-4133-8FC6-05F80B6DD4B4Q34997415-B3310BB0-5D34-452F-A825-7A0EE34915B1Q34998455-EFE51028-4AFC-4152-A2C0-7F65E945D8B1Q35021442-BA4647DB-185F-4EA2-8FAB-FC3FE5974B75Q35112695-38A112ED-279D-460C-BBFE-26D8C0C82412Q35113656-F7E12854-6F20-440E-934B-993F8C9762C4
P2860
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@ast
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@en
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@nl
type
label
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@ast
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@en
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@nl
prefLabel
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@ast
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@en
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@nl
P2093
P356
P1433
P1476
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
@en
P2093
P2888
P304
P356
10.1038/SJ.ONC.1204097
P407
P577
2000-12-01T00:00:00Z
P5875
P6179
1050913107